Once again, when it comes to surgery to treat breast cancer, less has been shown to be more.
Finalist essay from the 2009 Extraordinary Healer Award contest.
"We already know how extraordinary she is, and it's time to tell everyone else."
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
ROS1 may be a rare mutation in the cancer world, but a group of ROS1 patients have taken it upon themselves to search for answers.
A gynecologic-oncology clinical nurse specialist and one of this year’s CURE Ovarian Cancer Heroes discussed the lack of resources for patients with ovarian cancer and the need for more research.
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
“At 34, I have another chance to live the rest of my life with a consciousness that there's great purpose in the pain.”
Finalist essay for CURE's 2013 Extraordinary Healer Award for Oncology Nursing.
This essay, written by oncology nurse Karen Leary, Ruth & Raymond Perelman Center for Advanced Medicine, nominates fellow registered nurse and colleague Megan Lackaye for CURE®’s 2019 Extraordinary Healer® Award.
These advancements are changing the way many cancers are being treated.
The results of the most recent survey showed that 46% of patients have experienced a decline in their financial security and ability to pay for their care, and nearly 25% worry that they may lose their insurance as a result of the pandemic.
Distinguishing death with dignity from the right to die movement.
Life after a hysterectomy is one of the many challenges I have had to overcome.
Patients faced with cancer are also faced with tough uphill financial battles, but there are assistance programs that can help.
An Extraordinary Healer essay honoring MARY McMAHON, RN, OCN [THE CANCER INSTITUTE AT ST. FRANCIS HOSPITAL, EAST HILLS, NEW YORK]
Karuppiah Kannan, associate director at Takeda Pharmaceuticals, talks about the progress made in treating myeloma and where the field is going in the future.
As the number of patients and survivors continues to increase, it is important that clinician burnout is handled appropriately, explains Thomas A. Gallo.
“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.
Despite a national addiction crisis, opioids remain an appropriate choice for treating severe cancer pain.
Two women living with metastatic breast cancer that has spread to the brain describe the tools that are helping to keep them alive.
“For the patients that are nervous about how this is going to end, or what's going to happen, I would say that that's true for them outside of the COVID crisis because that's the same question they have about their cancer,” Dr. Scott A. Irwin said.
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Stem cells are cells that seem to have the ability to divide perpetually, but what does that mean in cancer?
Patients treated with Xtandi had higher rates of fatigue and pain than those who were treated with Zytiga and prednisone, resulting in a higher likelihood that they will reduce their treatment dose.